Drugs / RV1162
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01970618 | Oct 2013 → Nov 2014 | chronic obstructive pulmonary disease | Respivert Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04759807 Comparator | Jan → Dec 2021 | chronic obstructive pulmonary disease | Pulmatrix Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RV1162 | “The PUR1800 drug product intended for use in the proposed clinical study comprises bulk powder containing 5 wt% or 10 wt% RV1162 pre-metered into HPMC capsules for oral...” NCT04759807 ↗ |
| Route | Inhaled | “Treatment With Single and Repeat Doses of Inhaled RV1162” NCT01970618 ↗ |